Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13942540 | 0.99 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL13942548 | 0.88 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL13942543 | 0.78 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL4172546 | 0.77 | SMN1; SMN2 (0.57) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL13942534 | 0.77 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL4173129 | 0.75 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2HPGDLMNA | |
| SCHEMBL11943315 | 0.75 | MEN1 (0.57) | NPC1SMN1; SMN2HPGDLMNAPOLB | |
| SCHEMBL11943214 | 0.74 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL13219330 | 0.74 | ALDH1A1 (0.70) | NPC1RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL13942551 | 0.72 | RAB9A (0.42) | NPC1RAB9ASMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | NPC1 996/4885RAB9A 2534/4885SMN1; SMN2 89/4885 |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | NPC1 996/4885RAB9A 2534/4885SMN1; SMN2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.